Recent Posts

Updated Efficacy Data from GBT’s Phase 3 Study Show Statistically Significant and Sustained Improvements in Hemoglobin with Voxelotor

AMSTERDAM, The Netherlands, June 14, 2019 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (Nasdaq: GBT) today announced new …

Read More »

Bristol-Myers Squibb Announces Empliciti-Based Combination Showed Improvements Across All Efficacy Endpoints in Phase 2 Trial in Multiple Myeloma

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) today announced the presentation of updated data from …

Read More »

Enanta’s EDP-938 Achieved its Primary and Secondary Endpoints in Phase 2a Human Challenge Study in Healthy Adults with Respiratory Syncytial Virus

WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating …

Read More »

Phase 3 Study Showed that Genentech’s Rituxan is Superior to Standard of Care in Achieving Sustained Remission in Pemphigus Vulgaris

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: …

Read More »

Phase 3 Study of Savara’s Molgradex Fails to Meet its Primary Endpoint in Patients with Autoimmune Alveolar Pulmonary Proteinosis

AUSTIN, Texas–(BUSINESS WIRE)–Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced top line data …

Read More »

New Results from Phase 2 Trial Demonstrate Potential Clinical Benefit of IMV’s DPX-Survivac in Combination with Merck’s Keytruda in DLBCL Patients

DARTMOUTH, Nova Scotia–(BUSINESS WIRE)–IMV Inc. (Nasdaq:IMV; TSX:IMV), a clinical stage immuno-oncology corporation, today announced updated …

Read More »

Synlogic and Ginkgo Bioworks Enter Platform Collaboration for Accelerated Development of Novel Synthetic Biotic Medicines

CAMBRIDGE, Mass. & BOSTON–(BUSINESS WIRE)–Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage company applying synthetic biology to beneficial …

Read More »